Bisubstrate inhibitors for the enzyme catechol-O-methyltransferase (COMT): influence of inhibitor preorganisation and linker length between the two substrate moieties on binding affinity
- 26 November 2002
- journal article
- research article
- Published by Royal Society of Chemistry (RSC) in Organic & Biomolecular Chemistry
- Vol. 1 (1) , 42-49
- https://doi.org/10.1039/b208690p
Abstract
Inhibition of the enzyme catechol-O-methyltransferase (COMT) is an important approach in the treatment of Parkinson's disease. A series of new potent bisubstrate inhibitors for COMT, resulting from X-ray structure-based design and featuring adenosine and catechol moieties have been synthesised. Biological results show a large dependence of binding affinity on inhibitor preorganisation and the length of the linker between nucleoside and catechol moieties. The most potent bisubstrate inhibitor for COMT has an IC50 value of 9 nM. It exhibits competitive kinetics for the SAM and mixed inhibition kinetics for the catechol binding site. Its bisubstrate binding mode was confirmed by X-ray structure analysis of the ternary complex formed by the inhibitor, COMT and a Mg2+ ion.Keywords
This publication has 34 references indexed in Scilit:
- A Bisubstrate Analog Inhibitor of the Carboxyltransferase Component of Acetyl-CoA CarboxylaseBiochemical and Biophysical Research Communications, 2002
- X-ray crystallographic studies of serotonin N-acetyltransferase catalysis and inhibitionJournal of Molecular Biology, 2002
- Non-thiol farnesyltransferase inhibitors: structure–activity relationships of benzophenone-based bisubstrate analogue farnesyltransferase inhibitorsBioorganic & Medicinal Chemistry, 2001
- Double trouble.Nature Structural & Molecular Biology, 2001
- Mechanism-based design of a protein kinase inhibitor.Nature Structural & Molecular Biology, 2001
- Synthesis and In Vitro Evaluation of the Farnesyltransferase Inhibitor Pepticinnamin EChemistry – A European Journal, 1999
- Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patientsJournal of Neurology, Neurosurgery & Psychiatry, 1997
- Efficacy and safety of tolcapone in levodopa‐treated Parkinson's disease patients with “wearing‐off” phenomenon: a multicentre, double‐blind, randomized, placebo‐controlled trialEuropean Journal of Neurology, 1997
- Tolcapone Improves Motor Function and Reduces Levodopa Requirement in Patients with Parkinson's Disease Experiencing Motor FluctuationsNeurology, 1997
- Rational design of enzyme inhibitors: multisubstrate analog inhibitorsJournal of Medicinal Chemistry, 1989